Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.
|Videos|February 28, 2022
CORAL Study Brings Positive News for Adults With Depression
Author(s)Sagar V. Parikh, MD, FRCPC
Coadministration of zuranolone with a standard antidepressant yields positive outcomes.
Advertisement
Sagar Parikh, MD, FRCPC, shares news about the CORAL Study examining zuranolone treatment in patients with major depressive disorder, which demonstrated a rapid and statistically significant reduction in depressive symptoms at day 3 and over the 2-week treatment period.
To read more about this study, see:
Dr Parikh is a professor of Depression and Clinical Neuroscience, and Psychiatry Sciences, at the University of Michigan.
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Psychiatric Times
1
Olanzapine LAI (Weltruza) Receives FDA Approval for Schizophrenia
2
The New, Impending Adult ADHD Guidelines
3
Two New MDD Approvals: 5-HT1A Agonism and Adjunctive Atypical Antipsychotics
4
Moving Away From Treatment-Resistant Depression and Toward Difficult-to-Treat Depression
5